View Older Stories View More Recent Stories

Feb 15, 2025 10:00PM Biotech Q4 earnings preview: Goldman Sachs
Feb 13, 2025 08:05AM Johnson & Johnson (JNJ): New nipocalimab data published in mAbs journal
Feb 11, 2025 02:30PM Johnson & Johnson (JNJ) Puts Stroke Care Business Up For Sale - FT
Feb 3, 2025 07:10AM Johnson & Johnson (JNJ) PT Raised to $166 at Guggenheim
Jan 27, 2025 12:03PM Johnson & Johnson (JNJ) PT Raised to $166 at Barclays
Jan 23, 2025 01:22PM Johnson & Johnson (JNJ) PT Lowered to $158 at Bernstein Amid 'Tough Setup for 2025'
Jan 23, 2025 09:29AM Johnson & Johnson (JNJ) PT Lowered to $155 at Stifel
Jan 23, 2025 06:18AM Johnson & Johnson (JNJ) PT Lowered to $159 at BofA Securities
Jan 22, 2025 11:11AM Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
Jan 22, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Appoints Gary A. Shangold as Chief Medical Officer
Jan 22, 2025 08:15AM Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
Jan 22, 2025 06:22AM Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; offers 2025 guidance
Jan 21, 2025 11:12AM Johnson & Johnson (JNJ) call put ratio 3.5 calls to 1 put with a focus on January 24 weekly 155 calls into quarter results
Jan 21, 2025 08:05AM Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
Jan 21, 2025 05:38AM Johnson & Johnson (JNJ) calls more active than puts into quarter results
Jan 15, 2025 08:06AM Johnson & Johnson (JNJ): NDA initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive
Jan 13, 2025 09:54AM Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight
Jan 13, 2025 08:32AM Morgan Stanley Reiterates Equalweight Rating on Johnson & Johnson (JNJ)
Jan 13, 2025 06:32AM Johnson & Johnson (JNJ) Acquires Intra-Cellular Therapies (ITCI) for $132/sh Cash or $14.6B
Jan 13, 2025 06:27AM J&J (JNJ) in Talks to Buy Intra-Cellular (ITCI) - Bloomberg
Jan 8, 2025 12:30PM Johnson & Johnson (JNJ) Confirms Temporary Pause of US Eval and Varipulse Cases - Bloomberg
Jan 8, 2025 08:05AM Johnson & Johnson's (JNJ) Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
Jan 7, 2025 08:01AM Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Dec 17, 2024 05:27PM FDA Approves Celltrion's Steqeyma, Biosimilar to J&J's (JNJ) Stelara
Dec 17, 2024 10:00AM This consumer stock is a Top Pick for 2025 at Jefferies
Dec 16, 2024 04:12PM Johnson & Johnson (JNJ) Announces FDA Issues CRL For Rybrevant BLA
Dec 13, 2024 07:16AM RBC Capital on Johnson & Johnson (JNJ): 'Oncology Portfolio Built for Long-Term Growth'
Dec 11, 2024 09:44AM Truist: 'Potential Impact of Trump's Nominees on Biopharma'
Dec 2, 2024 08:02AM Johnson & Johnson (JNJ) seeks U.S. FDA approval for first pediatric indications for TREMFYA
Nov 22, 2024 08:02AM Johnson & Johnson (JNJ) seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
Nov 18, 2024 04:32PM Johnson & Johnson (JNJ) reports icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Nov 15, 2024 03:22AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.9 puts
Nov 14, 2024 10:02AM Johnson & Johnson (JNJ) reports nipocalimab demonstrated significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Nov 11, 2024 04:05PM Johnson & Johnson (JNJ): Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren
Nov 8, 2024 07:00AM Johnson & Johnson (JNJ) submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Oct 28, 2024 07:30AM Johnson & Johnson (JNJ): TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
Oct 20, 2024 08:42PM Starboard Value Builds Stake In Tylenol-Maker Kenvue - WSJ
Oct 16, 2024 06:50AM Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital
Oct 15, 2024 02:22PM Johnson & Johnson (JNJ) PT Raised to $170 at Stifel
Oct 15, 2024 08:20AM Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)
Oct 15, 2024 08:01AM Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
Oct 15, 2024 06:22AM Johnson & Johnson (JNJ) Tops Q3 EPS by 23c, Beats on Revenue
Oct 15, 2024 03:00AM Johnson & Johnson reports earnings ahead of the open. Here's what to know
Oct 14, 2024 11:14AM Johnson & Johnson (JNJ) October option implied volatility into quarter results
Oct 14, 2024 03:55AM Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
Oct 11, 2024 04:23AM Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
Oct 10, 2024 08:03AM Johnson & Johnson's (JNJ) TREMFYA demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
Oct 10, 2024 07:34AM Stifel Reiterates Hold Rating on Johnson & Johnson (JNJ) on V-Wave acquisition
Oct 10, 2024 05:28AM Wells Fargo Reiterates Equal Weight Rating on Johnson & Johnson (JNJ)
Oct 9, 2024 08:01AM Johnson & Johnson (JNJ) Completes Acquisition of V-Wave
View More Recent Stories View Older Stories